TchobroutskyG.Relation of diabetic control to the development of microvascular complications. Diabetologia1978; 15: 143–52.
2.
BrunnerFP, BryngerH, FassbinderW, Registry report: renal replacement therapy in patients with diabetic nephropathy, 1980–1985. Report from the European Dialysis and Transplant Association Registry. Nephrol Dial Transplant1988; 3: 585–95.
3.
The DCCT Research Group: The Diabetes Control and Complications Trial (DCCT): results of the feasibility study. Diabetes Care1987; 10: 1–19.
4.
MulhauserI, SantiagoJV, BolliGB. The frequency of severe hypoglycaemia during intensive insulin therapy (opinion leaders’ forum). Diab Nutr Metab, 1988; 1: 77–88.
5.
TchobroutskyG.Why do some diabetic patients develop severe microvascular complications?J Diabetic Complications1989; 3: 1–5.
6.
HansenKF, Dahl-JorgensenK, LauritzenT, Feldt-RasmussenB, Brinchmann-HansenO, DeckertT.Diabetic control and microvascular complications: the near-normoglycaemic experience. Diabetologia1986; 29: 677–84.
7.
BrownleeM, CeramiA.Glycosylated insulin complexed to concanavalin A: a biochemical basis for a closed-loop insulin delivery system. Diabetes1983; 32: 499–504.
8.
VelhoGD, ReachG, ThévenotD.The design and development of in vivo glucose sensors for artificial endocrine pancreas. In: TurnerAPF, KarubeI, WilsonHS, eds. Biosensors: Fundamentals and Applications, Barking, UK: Elsevier1987: 390–408.
9.
ShichiriM, KawamoriR, HakuiN, YamasakiY, AbeH.Closed-loop glycemic control with a wearable artificial endocrine pancreas. Variations in daily insulin requirements to glycemic responses. Diabetes1984; 33: 1200–2.
10.
MatthewsDR, BownE, BeckTW, An amperometric needle-type glucose sensor tested in rats and man. Diabetic medicine1987; 5: 248–52.
11.
PfeifferEF. Artificial pancreas: state of the art. International Journal of Artificial Organs, 1988; 11: 13–26.
12.
RebrinK, Hahn von DorscheH.Subcutaneous implanted glucose sensors as a part of the artificial B-cell (Abstract). Artificial Organs1989; 13: 174.
13.
KraegenEW, ChisholmDJ, MacNamaraME. Timing of insulin delivery with meals. Horm Metab Res, 1981; 13: 365–9.
RamsayRC, GoetzFC, SutherlandDER, Progression of diabetic retinopathy after pancreas transplantation for insulin-dependent diabetes. N Engl J Med1988; 318: 208–13.
16.
MauerSM, SutherlandDER, SteffesMW, Pancreatic islet transplantation. Effects on the glomerular lesions of experimental diabetes in the rat. Diabetes1974; 23: 748–53.
17.
HeringBJ, BretzelRG, FederlinK.Current status of clinical islet transplantation. Horm Metab Res1988; 20: 537–45.
18.
WarnockGL, RajotteRV. Critical mass of purified islets that induce normoglycemia after implantation into dogs. Diabetes1988; 37: 467–70.
19.
LaffertyKJ, ProwseSJ, SimeonovicCJ. Immunobiology of tissue transplantation: a return to the passenger leucocyte concept. Ann Rev Immunol1983; 1: 143–73.
20.
ReachG, JaffrinMY. Les pancréas bioartificiels. Médecine/Science1986; 2: 87–93.
21.
ChickWL, LikeAA, LaurisV, A hybrid artificial pancreas. Trans Am Soc Artif Intern Organs1975; 21: 8–13.
22.
TzeW, WongF, ChenL.Implantable artificial capillary unit for pancreatic islet allograft and xenograft. Diabetologia1979; 16: 247–52.
23.
OrsettiA, GuyC, ZouariN, DeffayF.Implantation du distributeur bio-artificiel d'insuline chez le chien utilisant des ilots d'espèce animale différente. C R Soc Biol1978; 172: 144–50.
24.
SunAM, ParisiusW, HealyG, VacekI, MacMorineH.The use in diabetic rats and monkeys of artificial capillary units containing cultured islets of Langerhans (artificial endocrine pancreas). Diabetes1977; 26: 1136–9.
25.
ReachG, PoussierPh, SausseA, AssanR, ItohM, GerichJE. Functional evaluation of a bioartificial pancreas using isolated islets perfused with blood ultrafiltrate. Diabetes1981; 30: 296–301.
26.
ReachG, JaffrinMY, DesjeuxJF. A U-shaped bioartificial pancreas with rapid glucose insulin kinetics: in vitro evaluation and kinetic modelling. Diabetes1984; 33: 752–61.
27.
O'SheaGM, GoosenMFA, SunAM. Prolonged survival of transplanted islets of Langerhans encapsulated in a biocompatible membrane. Biochim Biophys Acta1984; 804: 133–6.
28.
O'SheaGM, SunAM. Encapsulation of rat islets prolongs xenograft survival in diabetic mice. Diabetes1986; 35: 943–6.
29.
AltmanJJ, HoulbertD, CallardP, Long-term plasma glucose normalization in experimental diabetic rats with macroencapsulated implants of benign human insulinoma. Diabetes1986; 35: 625–33.
30.
SparksRE, MasonNS, FinleyTC, ScharpDW. Development, testing, and modelling of an islet transplantation chamber. Trans Am Soc Artif Intern Organs1982; 28: 229–31.
31.
ReachG, JaffrinMY, VanhoutteC, DesjeuxJF. Importance of convective transport in a model of bioartificial pancreas. Am Soc Artif Intern Organs1984; 7: 85–90.
32.
ReachG, ChenardPS, DarquyS, Kinetics of insulin delivery by a bioartificial pancreas: in vivo evaluation in conscious normal rats. Progress in Artif Organs1985: 621–6.
33.
LepeintreJ, BriandetH, MoussyF, Ex vivo evaluation in normal dogs of insulin release by a bioartificial pancreas containing isolated rat islets of Langerhans. Artif Organs1990; 14: 20–7.
34.
TzeWJ, TaiJ, WongFC, DavisHR. Studies with implantable artificial capillary units containing rat islets on diabetic dogs. Diabetologia1980; 19: 541–5.
35.
BrownL, MunozC, SiemerL, EdelmanE, LangerR.Controlled release of insulin from polymer matrices. Control of diabetes in rats. Diabetes1986; 35: 692–7.
36.
ArakiY, SolomonBA, BasileRM, ChickWL. Biohybrid artificial pancreas. Long term insulin secretion by devices seeded with canine islets. Diabetes1985; 34: 850–4.
ChicheporticheD, ReachG.Kinetics of insulin release by microencapsulated islets: effect of the size of the microcapsule. Diabetologia1988; 31: 54–7.
39.
DarquyS, ReachG.Immunoisolation of pancreatic B cells by microencapsulation: an in vitro study. Diabetologia1985; 28: 776–80.
40.
MoussyF, RouchetteJ, ReachG.In vitro evaluation of a bioartificial pancreas under various hemodynamic conditions. Artificial Organs1989; 13: 109–15.
41.
JaffrinMY, ReachG, NoteletD.Analysis of ultrafiltration and mass transfer in a bioartificial pancreas. J Biomechanical Engeneering Trans ASME1988; 110: 1–10.
42.
MoussyF, VelhoG, AubertN, Absence of effect of heparin on insulin secretion. Artificial Organs1988; 12: 137–42.
43.
PenfornisF, IcardP, GotheilC, Réaction tissulaire à des pancréas bioartificiels extravasculaires chez le rat, la souris, et le porc. Diabète et Métabolisme.1989; 15: III Abstract.
44.
RickerAT, StobetgerSM, HalbanPA, EisenbarthGS, Bonner-WeirS.Hyperimmune response to micro-encapsulated xenogenic tissue in non-obese diabetic mice. In: JaworskiMA, MolnarGD, RajotteRV, SinghB, eds. The immunology of diabetes mellitus.Amsterdam: Elsevier1986; 193–200.
45.
RickerAT, BhatiaV, Bonneir-WeirS, EisenbarthGS. Microencapsulated islet graft in NOD mouse: dexamethasone and inflammatory response (Abstract). Diabetes1988; 37: 19.
46.
CalafioreR, CalcinaroF, KohN, AlejandroR.Xenotransplantation of microencapsulated canine islets in diabetic NOD mice: prolongation of graft survival with superoxide scavengers (Abstract). Diabetologia1987; 37: 504.
47.
FischerU, RebrinK, von WoedtkeT.Biocompatibility of glucose sensors: why is it a key issue?Proceedings of the Workshop “Clinical Aspects of In Vivo Sensing” of a Biomedical Engineering Action of the European Community (Chemical sensors for in vivo monitoring), Lyon, France, March 8–10, 1989.
48.
PukelC, BaquerizoH, RabinovitchA.Destruction of rat islet cell monolayer by cytokines: synergistic interactions of interferon-gamma, tumor necrosis factor, and interleukin-1. Diabetes1988; 37: 133–6.
49.
ColeDR, WaterfallM, BairdJD. Cytokine-mediated destruction of micro-encapsulated pancreatic islets in vitro: a mechanism for graft failure?(Abstract) Diabetic Medicine1989; 6 Supp 1: A5.
50.
KnatterudGL, FischerM.International study group on implantable insulin devices registry. Diabetes, Nutrition & Metabolism, Clinical and Experimental1988; 1: 323–2328.
51.
WilliamsDF. A list of terms from the European Society for Biomaterials. Enjeux1986; 74: 44–5.